Providers

How strategic partnerships in oncology can enhance patient care by addressing diverse needs through collaboration.

The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.

Experts discuss the evolving dynamics between payers and providers in oncology, emphasizing value-based care, data transparency, and collaborative reform opportunities.

Oncology leaders warn that declining reimbursements and policy gaps threaten patient access and drive inequities in cancer care.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Psychotherapy is key in reducing risk of depression relapse when tapering antidepressant medication.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

A review of 560 FDA-approved drugs found the FDAAA did not change overall time to first postmarket safety action, but some actions occurred earlier.

As value-based care mandates expand, a new survey highlights documentation burdens and burnout risks.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.

Within the same physician groups, 2-sided risk in Medicare Advantage (MA) was associated with higher quality and lower utilization for dually eligible beneficiaries compared with fee-for-service MA and traditional Medicare.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed key aspects of the KEYNOTE-B96 trial of paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

Medicaid expansion has enhanced cancer care in Louisiana, boosting access to treatments like CAR T-cell therapy and improving breast cancer screening initiatives.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

A case-crossover study found that extreme heat increased mortality between 10% and 18%, with higher risks in vulnerable groups.

Svetlana Barbarash, MD, outlines the lack of cardiologists and transplant services in Las Vegas and the policy changes needed to close gender gaps in care.

Onasemnogene abeparvovec-brve is now the first gene replacement therapy approved for spinal muscular atrophy in patients 2 years and older.